ACC 2008: Analysts keep faith with Medtronic after CRT trial misses endpoint
This article was originally published in Clinica
Executive Summary
Medtronic's REVERSE study, examining the suitability of cardiac resynchronisation therapy (CRT) in patients with mild heart failure, has missed its primary endpoint. The failure of the trial, presented at the annual meeting of the American College of Cardiology (ACC), raises questions about what constitutes appropriate pacemaker use.